Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 14;13:992060. doi: 10.3389/fimmu.2022.992060

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Wang, Wang, Li, Hu, Wu, Yuan, Wu, Yuan and Yuan

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

The associations of the APscore with immunotherapy response, immune microenvironment, and survival in aGC patients. (A) The relationship of the APscore with indicators of immunotherapy response predicted by the TIDE algorithm. (B) The relationship of the APscore with infiltration of the 22 immune cells calculated by the CIBERSORT algorithm. (C) The interrelations of the APscore with PCA genes scores of important biological pathways of GC. The white squares represent no statistically significant. (D) Kaplan-Meier survival plots in both groups of 467 aGC patients. (E) Comparison of the tumor purity, estimate, immune, and stromal scores between the high-APscore and low APscore-groups. (F) Comparison of the 22 immune cells proportions between the high-APscore and low APscore-groups. Asterisks denote significant differences (*p< 0.05; **p< 0.01; ***p< 0.001).